TCGA-77-A5FZ-01A-31R-A27Q-07
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 64
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.600
- IL6_JAK_STAT3_SIGNALING+0.600
- INFLAMMATORY_RESPONSE+0.540
- TNFA_SIGNALING_VIA_NFKB+0.540
- INTERFERON_GAMMA_RESPONSE+0.500
- COMPLEMENT+0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- ANGIOGENESIS+0.450
- COAGULATION+0.410
- KRAS_SIGNALING_UP+0.410
Top 10 suppressed
- MYC_TARGETS_V2-0.640
- MYC_TARGETS_V1-0.630
- E2F_TARGETS-0.620
- G2M_CHECKPOINT-0.530
- MTORC1_SIGNALING-0.470
- OXIDATIVE_PHOSPHORYLATION-0.470
- GLYCOLYSIS-0.410
- DNA_REPAIR-0.400
- CHOLESTEROL_HOMEOSTASIS-0.370
- PROTEIN_SECRETION-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-44-A47G-01A-21R-A24H-07 | — | cohortA1 | 0.951 |
| 2 | SRR2771286 | — | — | 0.950 |
| 3 | 59f108c6-677f-4cf2-89fd-6bd15133dd6f | — | — | 0.947 |
| 4 | TCGA-99-8028-01A-11R-2241-07 | — | cohortMD2 | 0.945 |
| 5 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.944 |
| 6 | TCGA-98-A53C-01A-11R-A262-07 | — | cohortMD2 | 0.942 |
| 7 | C3N-02923 | — | cohortMD2 | 0.938 |
| 8 | c6396737-3587-46a7-808d-963eebe41224 | — | — | 0.937 |
| 9 | X038167c2.c7d9.47a2.9172.1cfe391c8131 | — | cohortMD2 | 0.935 |
| 10 | ERR2208937 | — | — | 0.934 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.600 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.540 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.540 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| COMPLEMENT | 0.480 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| COAGULATION | 0.410 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.410 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| MYOGENESIS | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| APOPTOSIS | 0.160 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |